Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net income	$ 958,000	$ 735,000
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	351,000	405,000
Impairment of intangible assets	404,000	0
Release of accounts payable no longer owed	(406,000)	0
Accretion of financing instruments and amortization of prepaid financing costs	192,000	239,000
Compensation expense on employee stock options	31,000	104,000
Gain on common stock sales of iBio, Inc.		(48,000)
Change in fair value of derivative instruments	64,000	(705,000)
Allowance for doubtful accounts	30,000	(20,000)
Gain on deposal of property and equipment	(15,000)	(3,000)
Changes in operating assets and liabilities:
Accounts receivable	(527,000)	(440,000)
Inventories	(1,978,000)	(79,000)
Prepaid expenses and other current assets	(99,000)	(42,000)
Accounts payable	727,000	(488,000)
Accrued expenses and other current liabilities	(326,000)	229,000
Net cash used in operating activities	(594,000)	(113,000)
Cash flows from investing activities:
Purchase of property and equipment	(109,000)	(235,000)
Proceeds from sale of property and equipment	2,000
Proceeds from common stock sales of iBio, Inc.		79,000
Net cash used in investing activities	(107,000)	(156,000)
Cash flows from financing activities:
Advances under revolving credit facility	41,166,000	36,993,000
Repayments of advances under revolving credit facility	(41,418,000)	(36,652,000)
Proceeds from Line of Credit Note	43,000	307,000
Repayments under term notes payable	(620,000)	(616,000)
Repayments under capitalized lease obligations	(121,000)	(143,000)
Proceeds from term note payable	1,975,000
Net cash provided by (used in) financing activities	1,025,000	(111,000)
Net increase (decrease) in cash	324,000	(380,000)
Cash at beginning of fiscal year	71,000	451,000
Cash at end of fiscal year	395,000	71,000
Supplemental disclosures of cash flow information:
Interest	745,000	714,000
Income taxes	168,000	158,000
Supplemental disclosures of non-cash transactions:
Accretion on embedded derivative feature of Convertible Note Payable	86,000	110,000
Financing on capitalized lease obligations	$ 317,000	$ 185,000